<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Reddy, Vivek Y.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Watchman Superior to Warfarin for Stroke Prophylaxis in Atrial Fibrillation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">Long-term data from the Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation trial [PROTECT AF; NCT00129545] indicate that left atrial appendage (LAA) closure with the Watchman provides superior protection from stroke compared with warfarin. The data also showed that Watchman LAA occlusion filter is associated with a 40% reduction in stroke/systemic embolism/cardiovascular (CV) death, a 60% reduction in CV mortality, and a 34% reduction in all-cause mortality.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>